Clik here to view.
Morinaga Milk Obtains FDA GRAS Notification for its Probiotic
TOKYO Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a leading Japanese dairy product company, today announced its proprietary probiotic Bifidobacterium longum subsp. infantis M-63 has received FDA...
View ArticleClik here to view.
AdvanCell Closes A$18M Series B Funding Led by Morningside
SYDNEY AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing of an A$18...
View ArticleClik here to view.
Chungcheongbuk-do Province Hosts 2022 CHUNGBUK BEST PRODUCT PROMOTION to...
CHEONGJU, South Korea & JAKARTA, Indonesia Chungcheongbuk-do has started to secure export channels for promising exporters in North Chungcheong Province to the Indonesian market. 2022 CHUNGBUK...
View ArticleClik here to view.
森永乳业旗下益生菌通过FDA GRAS Notification认证
东京 (美国商业资讯)–领先的日本乳制品公司森永乳业株式会社(Morinaga Milk Industry Co., Ltd., TOKYO:2264)今天宣布，其专利益生菌长双歧杆菌亚种婴儿双歧杆菌M-63已通过关于用于足月婴儿配方食品和普通食品的FDA GRAS（一般公认安全）认证。...
View ArticleClik here to view.
AdvanCell完成由晨兴创投领投的1,800万澳元B轮融资
悉尼 (美国商业资讯)–澳大利亚放射性药物公司AdvanCell今天宣布，已完成由晨兴创投领投的1,800万澳元B轮融资。该公司拥有被称为靶向阿尔法疗法(Targeted Alpha Therapy)的革命性癌症治疗平台技术。 AdvanCell创始人兼首席执行官Andrew...
View ArticleClik here to view.
Medisca发布新品牌标识和“健康合作伙伴”企业定位
蒙特利尔 (美国商业资讯)–在成功地重新定义、塑造和影响医药合成行业标准30年之后，Medisca自豪地发布了新的全球品牌标识和企业定位，以反映其增长历程、多元化特征和机会。Medisca成立于1989年，从一家仅有数名员工的小公司成长为全球性企业，在教育、制造、供应链和分析测试领域拥有众多战略合作伙伴，致力于交付定制化解决方案，同时坚定不移地专注于质量和创新。...
View ArticleClik here to view.
Clik here to view.
Sonde Health Inks Multi-Year Partnership with Koye Pharmaceuticals
BOSTON Sonde Health, a leading enterprise vocal biomarker company, has signed a multi-year agreement with Koye Pharmaceuticals, a specialty pharma organization focused on the Indian Pharmaceutical...
View ArticleClik here to view.
CANbridge Announces Financial Results and Corporate Updates for Six Months...
BEIJING & BURLINGTON, Mass. CANbridge Pharmaceuticals, Inc. (“CANbridge,” 1228.HK), a China and U.S.-based global biopharmaceutical company committed to the research, development and...
View ArticleClik here to view.
百奥赛图深化与默克合作
中国北京与德国达姆施塔特 (美国商业资讯) –百奥赛图（北京）医药科技股份有限公司（“百奥赛图”）与默克就使用百奥赛图的RenMice™平台签订了全球许可协议。根据协议条款，默克将可全权使用百奥赛图的RenMice™平台，以发现和开发针对不限数量的药物靶点的全人抗体疗法。默克将负责所有临床开发、生产和商业化；此外，还将支付百奥赛图开发和监管里程碑费用。此份正式协议是在初步评估期后达成的。...
View ArticleClik here to view.
Biocytogen Expands Partnership with Merck
BEIJING & DARMSTADT, Germany Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMice™ platform....
View ArticleClik here to view.
Clik here to view.
Clinical Data from the LIGHT-UP Study Presented at the International Congress...
BOSTON Gelesis Holdings Inc. (NYSE: GLS) (“Gelesis” or the “Company”) the maker of Plenity for weight management, today released a poster presentation at the International Congress of Endocrinology...
View ArticleClik here to view.
Biocytogen Expands Partnership with Merck
BEIJING & DARMSTADT, Germany Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”) entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMiceTM platform....
View ArticleClik here to view.
Mary Kay Announces Outcomes of SDG Pilot Village Project in China (2017-2021)...
DALLAS Rural women comprise a quarter of the world’s population and are the backbone of their economies, comprising an estimated 40% of the agricultural labor force in developing countries as...
View ArticleClik here to view.
AdvanCellがモーニングサイド主導のシリーズB資金調達で1800万豪ドルの調達を完了
シドニー （ビジネスワイヤ） — 革新的ながん治療法である標的α線治療のプラットフォーム技術を有するオーストラリアの放射性医薬品企業AdvanCellは本日、モーニングサイドが主導するシリーズBの資金調達で1800万豪ドルを調達したと発表しました。 AdvanCellの最高経営責任者（CEO）で創設者のAndrew...
View ArticleClik here to view.
ポリピルが心筋梗塞後に治療された患者の心血管死亡率を33%低減させる
マドリード （ビジネスワイヤ） — CNICとFerrerが開発したポリピルは、3種類の薬剤（アスピリン、アンジオテンシン変換酵素（ACE）阻害剤、スタチン）を含み、心臓発作の既往がある人における二次有害心血管イベントの予防に効果的です。ポリピルは、この集団における心血管系の原因による死亡率を33%低減させます。...
View ArticleClik here to view.
Clik here to view.
InnoCare Announces the Acceptance of the Biologics License Application for...
BEIJING InnoCare Pharma (HKEX: 09969) announced today the acceptance of the biologics license application (BLA) for tafasitamab in combination with lenalidomide for adult patients with relapsed or...
View ArticleClik here to view.
Cerebras Systems Enables GPU-Impossible™ Long Sequence Lengths Improving...
SUNNYVALE, Calif. Cerebras Systems, the pioneer in accelerating artificial intelligence (AI) compute, released yet another industry-first capability today. Customers can now rapidly train...
View Article